Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
3.900
-0.100 (-2.50%)
At close: Jun 5, 2025, 4:00 PM
3.840
-0.060 (-1.54%)
After-hours: Jun 5, 2025, 4:44 PM EDT
Jaguar Health Revenue
Jaguar Health had revenue of $2.21M in the quarter ending March 31, 2025, a decrease of -5.83%. This brings the company's revenue in the last twelve months to $11.55M, up 13.93% year-over-year. In the year 2024, Jaguar Health had annual revenue of $11.69M with 19.75% growth.
Revenue (ttm)
$11.55M
Revenue Growth
+13.93%
P/S Ratio
0.15
Revenue / Employee
$235,755
Employees
49
Market Cap
4.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
JAGX News
- 15 days ago - Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Accesswire
- 16 days ago - First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID) - Accesswire
- 20 days ago - Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Jaguar Health Reports First Quarter 2025 Financials - Accesswire
- 22 days ago - Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates - Accesswire
- 4 weeks ago - Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - Accesswire
- 4 weeks ago - Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts - Accesswire
- 5 weeks ago - Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients - Accesswire